Optiscan Imaging Enters Collaboration Agreement with US Firm for Applications for Imaging Contrast Agent, Shares Jump 9%

MT Newswires Live

06/23

Optiscan Imaging (ASX:OIL) entered into an exclusive collaboration agreement with Long Grove Pharmaceuticals to develop new intended applications for Long Grove's intravenous drug, fluorescein sodium, or AK-FLOUR, according to a Monday Australian bourse filing.

AK-FLOUR is a contrast agent specifically used with Optiscan's current generation of fluorescence-based endomicroscopic imaging devices for surgical applications. The firms will develop new intended uses for the intravenous fluorescein sodium contrast agent.

AK-FLOUR will be used exclusively in US clinical studies and trials with Optiscan's InVue device in a range of clinical applications, starting with breast surgery. Data from the collaboration studies will be used to support Optiscan's US Food and Drug Administration regulatory submissions for its InVue surgical device.

Its shares jumped 9% in recent trading on Monday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2545334450"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545334450\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2545334450?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-23 09:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545334450","market":"sh","top_or_hot":-1,"title":"Optiscan Imaging Enters Collaboration Agreement with US Firm for Applications for Imaging Contrast Agent, Shares Jump 9%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/OILN.AU\">Optiscan Imaging</a> (ASX:OIL) entered into an exclusive collaboration agreement with Long Grove Pharmaceuticals to develop new intended applications for Long Grove's intravenous drug, fluorescein sodium, or AK-FLOUR, according to a Monday Australian bourse filing.</p><p>AK-FLOUR is a contrast agent specifically used with Optiscan's current generation of fluorescence-based endomicroscopic imaging devices for surgical applications. The firms will develop new intended uses for the intravenous fluorescein sodium contrast agent.</p><p>AK-FLOUR will be used exclusively in US clinical studies and trials with Optiscan's InVue device in a range of clinical applications, starting with breast surgery. Data from the collaboration studies will be used to support Optiscan's US Food and Drug Administration regulatory submissions for its InVue surgical device.</p><p>Its shares jumped 9% in recent trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Optiscan Imaging Enters Collaboration Agreement with US Firm for Applications for Imaging Contrast Agent, Shares Jump 9%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOptiscan Imaging Enters Collaboration Agreement with US Firm for Applications for Imaging Contrast Agent, Shares Jump 9%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-06-23 09:59</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/OILN.AU\">Optiscan Imaging</a> (ASX:OIL) entered into an exclusive collaboration agreement with Long Grove Pharmaceuticals to develop new intended applications for Long Grove's intravenous drug, fluorescein sodium, or AK-FLOUR, according to a Monday Australian bourse filing.</p><p>AK-FLOUR is a contrast agent specifically used with Optiscan's current generation of fluorescence-based endomicroscopic imaging devices for surgical applications. The firms will develop new intended uses for the intravenous fluorescein sodium contrast agent.</p><p>AK-FLOUR will be used exclusively in US clinical studies and trials with Optiscan's InVue device in a range of clinical applications, starting with breast surgery. Data from the collaboration studies will be used to support Optiscan's US Food and Drug Administration regulatory submissions for its InVue surgical device.</p><p>Its shares jumped 9% in recent trading on Monday.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7007","symbol_name":"醫療保健設備","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2545334450","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545334450","pubTimestamp":1750643944,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Optiscan Imaging  entered into an exclusive collaboration agreement with Long Grove Pharmaceuticals to develop new intended applications for Long Grove's intravenous drug, fluorescein sodium, or AK-FLOUR, according to a Monday Australian bourse filing.AK-FLOUR is a contrast agent specifically used with Optiscan's current generation of fluorescence-based endomicroscopic imaging devices for surgical applications. The firms will develop new intended uses for the intravenous fluorescein sodium contrast agent.AK-FLOUR will be used exclusively in US clinical studies and trials with Optiscan's InVue device in a range of clinical applications, starting with breast surgery. Data from the collaboration studies will be used to support Optiscan's US Food and Drug Administration regulatory submissions for its InVue surgical device.Its shares jumped 9% in recent trading on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7007":"医疗保健设备","OIL.AU":"OPTISCAN IMAGING LIMITED"},"translate_title":"Optiscan Imaging与美国公司就成像造影剂应用达成合作协议，股价上涨9%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OIL.AU":0.9},"content_text":"Optiscan Imaging (ASX:OIL) entered into an exclusive collaboration agreement with Long Grove Pharmaceuticals to develop new intended applications for Long Grove's intravenous drug, fluorescein sodium, or AK-FLOUR, according to a Monday Australian bourse filing.AK-FLOUR is a contrast agent specifically used with Optiscan's current generation of fluorescence-based endomicroscopic imaging devices for surgical applications. The firms will develop new intended uses for the intravenous fluorescein sodium contrast agent.AK-FLOUR will be used exclusively in US clinical studies and trials with Optiscan's InVue device in a range of clinical applications, starting with breast surgery. Data from the collaboration studies will be used to support Optiscan's US Food and Drug Administration regulatory submissions for its InVue surgical device.Its shares jumped 9% in recent trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}